Pàgina inicial > Articles > Resultats de la cerca: Multiple Sclerosis

Articles

  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Articles 124 registres trobats  anterior11 - 20següentfinal  anar al registre: La cerca s'ha fet en 0.01 segons. 
11.
18 p, 1.7 MB Epstein-Barr Virus and Multiple Sclerosis : A Convoluted Interaction and the Opportunity to Unravel Predictive Biomarkers / Ortega-Hernandez, Oscar-Danilo (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Cáceres, Eva María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Presas-Rodríguez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Since the early 1980s, Epstein-Barr virus (EBV) infection has been described as one of the main risk factors for developing multiple sclerosis (MS), and recently, new epidemiological evidence has reinforced this premise. [...]
2023 - 10.3390/ijms24087407
International journal of molecular sciences, Vol. 24 (april 2023)  
Registre complet - Creative Commons
12.
12 p, 2.6 MB Traffic Lights Intervention Reduces Therapeutic Inertia : A Randomized Controlled Trial in Multiple Sclerosis Care / Saposnik, Gustavo (St. Michael's Hospital, Toronto) ; Mamdani, Muhammad (Li Ka Shing Centre for Healthcare Analytics Research and Training (LKS-CHART)) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Terzaghi, Maria (St. Michael's Hospital, Toronto) ; Silva, Berenice (Institute of Neuroscience Buenos Aires (INEBA)) ; Saladino, Maria Laura (Institute of Neuroscience Buenos Aires (INEBA)) ; Tobler, Philippe N. (University of Zurich) ; Caceres, Fernando (Institute of Neuroscience Buenos Aires (INEBA)) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Therapeutic inertia (TI) is a common phenomenon among physicians who care for patients with chronic conditions. We evaluated the efficacy of the traffic light system (TLS) educational intervention to reduce TI among neurologists with MS expertise. [...]
2019 - 10.1177/2381468319855642
MDM Policy and Practice, Vol. 4 Núm. 1 (2019) , p. 1-12  
Registre complet - Creative Commons
13.
5 p, 336.0 KB Does attendance at the ECTRIMS congress impact on therapeutic decisions in multiple sclerosis care? / Saposnik, Gustavo (University of Zurich) ; Maurino, Jorge (University of Buenos Aires) ; Sempere, Angel P. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Terzaghi, Maria A. (St. Michael's Hospital, Toronto) ; Amato, Maria Pia (University of Florence) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona. Departament de Medicina
Conferences traditionally play an important role in the ongoing medical education of healthcare professionals. We assessed the influence of attending the ECTRIMS congress on therapeutic decision-making in multiple sclerosis (MS) care. [...]
2019 - 10.1177/2055217319835226
Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 5 Núm. 1 (1-3 2019) , p. 205521731983522  
Registre complet - Creative Commons
14.
10 p, 1.1 MB The Multiple Sclerosis Care Unit / Sørensen, Per S (Copenhagen University Hospital) ; Giovannoni, Gavin (Queen Mary University of London) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Thalheim, Christoph (European Multiple Sclerosis Platform, Brussels) ; Zaratin, Paola (Multiple Sclerosis International Federation (MSIF)) ; Comi, Giancarlo (San Raffaele Hospital, Milan) ; Universitat Autònoma de Barcelona. Departament de Medicina
Treatment of multiple sclerosis (MS) has become increasingly multifaceted and comprises not only a variety of disease-modifying drugs with different mechanism of action but also a wide range of symptomatic therapies. [...]
2019 - 10.1177/1352458518807082
Multiple sclerosis, Vol. 25 Núm. 5 (april 2019) , p. 627-636  
Registre complet - Creative Commons
15.
11 p, 1.0 MB Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study / Balk, Lisanne J. (Vrije Universiteit Amsterdam) ; Coric, Danko (Vrije Universiteit Amsterdam) ; Knier, Benjamin (Technische Universität München) ; Zimmermann, Hanna G. (Charité - Universitätsmedizin Berlin) ; Behbehani, Raed (Ibn Sina Hospital, Kuwait) ; Alroughani, Raed (Amiri Hospital, Kuwait) ; Martinez-Lapiscina, Elena H. (Hospital Clínic i Provincial de Barcelona) ; Brandt, Alexander U. (Charité - Universitätsmedizin Berlin) ; Sánchez-Dalmau, Bernardo (Hospital Clínic i Provincial de Barcelona) ; Vidal-Jordana, Angela (Hospital Universitari Vall d'Hebron) ; Albrecht, Philipp (Heinrich Heine University) ; Koska, Valeria (Heinrich Heine University) ; Havla, Joachim (Ludwig-Maximilians Universitaet Muenchen) ; Pisa, Marco (Vita-Salute San Raffaele University) ; Nolan, Rachel C. (New York University School of Medicine) ; Leocani, Letizia (Vita-Salute San Raffaele University) ; Paul, Friedemann (Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin) ; Aktas, Orhan (Heinrich Heine University) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Balcer, Laura J. (New York University School of Medicine) ; Villoslada, Pablo (Hospital Clínic i Provincial de Barcelona) ; Outteryck, Olivier (Université Lille) ; Korn, Thomas (Munich Cluster for Systems Neurology (SyNergy)) ; Petzold, Axel (Moorfields Eye Hospital & The National Hospital for Neurology and Neurosurgery) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: The association of peripapillary retinal nerve fibre layer (pRNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness with neurodegeneration in multiple sclerosis (MS) is well established. [...]
2019 - 10.1177/2055217319871582
Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 5 Núm. 3 (2019)  
Registre complet - Creative Commons
16.
14 p, 1.0 MB Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis : 6-year results from the SELECTED open-label extension study / Gold, Ralf (Ruhr-University Bochum) ; Radue, Ernst-Wilhem (University Hospital Basel (Basilea, Suïssa)) ; Giovannoni, Gavin (Queen Mary University of London) ; Selmaj, Krzysztof. (University of Warmia and Mazury) ; Havrdova, Eva Kubala (Charles University) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Stefoski, Dusan (Rush University Medical Center) ; Sprenger, Till (DKD Helios Klinik Wiesbaden) ; Robinson, Randy R. (AbbVie Inc.) ; Fam, Sami (Biogen) ; Smith, Jonathan (Biogen) ; Chalkias, Spyros (Biogen) ; Giannattasio, Giorgio (Biogen) ; Lima, Gabriel (Biogen) ; Castro-Borrero, Wanda (Biogen) ; Universitat Autònoma de Barcelona
Objective: SELECTED, an open-label extension study, evaluated daclizumab beta treatment for up to 6 years in participants with relapsing multiple sclerosis who completed the randomized SELECT/SELECTION studies. [...]
2020 - 10.1007/s00415-020-09835-y
Journal of Neurology, Vol. 267 Núm. 10 (january 2020) , p. 2851-2864  
Registre complet - Creative Commons
17.
11 p, 473.7 KB Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting : PROTEC / Berger, Thomas (Universitätsklinik für Neurologie) ; Brochet, B. (Groupe Hospitalier Pellegrin Hôpital Pellegrin) ; Brambilla, L. (IRCCS Foundation Neurological Institute Carlo Besta) ; Giacomini, P.S. (Montreal Neurological Institute Hospital) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Vasco Salgado, A (Hospital Professor Doutor Fernando Fonseca) ; Su, R (Biogen, USA) ; Bretagne, A (Biogen International GmbH) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Patient-reported outcomes (PRO) and clinical outcomes give a broad assessment of relapsing-remitting multiple sclerosis (RRMS) disease. Objective: The aim is to evaluate the effectiveness of delayed-release dimethyl fumarate (DMF) on disease activity and PROs in patients with RRMS in the clinic. [...]
2019 - 10.1177/2055217319887191
Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 5 Núm. 4 (2019)  
Registre complet - Creative Commons
18.
17 p, 300.8 KB Expert opinion on the use of cladribine tablets in clinical practice / Sørensen, Per Soelberg (University of Copenhagen) ; Centonze, Diego (Unit of Neurology and Neurorehabilitation) ; Giovannoni, Gavin (Queen Mary University of London) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Selchen, Daniel (St. Michael's Hospital, Toronto) ; Vermersch, Patrick (Univ. Lille) ; Wiendl, Heinz (University of Münster) ; Yamout, Bassem (American University of Beirut) ; Salloukh, Hashem (Ares Trading S.A. Merck Serono S.A) ; Rieckmann, Peter (University of Erlangen) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Gaps in current product labels and a lack of detailed clinical guidelines leaves clinicians' questions on the practical management of patients receiving cladribine tablets for the treatment of relapsing multiple sclerosis (MS) unanswered. [...]
2020 - 10.1177/1756286420935019
Therapeutic Advances in Neurological Disorders, Vol. 13 (2020)  
Registre complet - Creative Commons
19.
12 p, 888.5 KB Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis / Turner, Benjamin (The Royal London Hospital) ; Cree, Bruce A. C (University of California) ; Kappos, Ludwig (University Hospital Basel (Basilea, Suïssa)) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Papeix, Caroline (Pitié-Salpêtrière Hospital) ; Wolinsky, Jerry S. (The University of Texas Health Science Center at Houston (UTHealth)) ; Buffels, Regine (F. Hoffmann-La Roche Ltd) ; Fiore, Damian (Genentech. Inc) ; Garren, Hideki (Genentech. Inc) ; Han, Jian (Genentech. Inc) ; Hauser, Stephen L. (University of California) ; Universitat Autònoma de Barcelona. Departament de Medicina
Objective: The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has been reported; here we present subgroup analyses of efficacy endpoints from the pooled OPERA I and OPERA II populations. [...]
2019 - 10.1007/s00415-019-09248-6
Journal of Neurology, Vol. 266 Núm. 5 (may 2019) , p. 1182-1193  
Registre complet - Creative Commons
20.
8 p, 915.8 KB Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis / Leist, Thomas (Jefferson University) ; Cook, S. (New Jersey Medical School) ; Comi, Giancarlo (Università Vita-Salute San Raffaele) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Giovannoni, Gavin (Queen Mary University of London) ; Nolting, A. (Merck KGaA) ; Damian, D. (Merck KGaA) ; Syed, S. (Merck KGaA) ; Galazka, Andrew (Merck KGaA) ; Universitat Autònoma de Barcelona
Background: Long-term safety data are of particular interest for any newly approved treatment in multiple sclerosis such as cladribine tablets 10 mg (MAVENCLAD®; 3. 5 mg/kg cumulative dose over 2 years, referred to as cladribine tablets 3. [...]
2020 - 10.1016/j.msard.2020.102572
Multiple Sclerosis and Related Disorders, Vol. 46 (november 2020) , p. 102572  
Registre complet - Creative Commons

Articles : 124 registres trobats   anterior11 - 20següentfinal  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem